SUNPHARMA.NSSUNPHARMA.NSNSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank43
3Y CAGR-15.7%
5Y CAGR+5.7%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-15.7%/yr
Annual compound
5Y CAGR
+5.7%/yr
Recent deceleration
Percentile
P43
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
20250.85%
202435.53%
20238.22%
20221.41%
20219.23%
20200.64%
2019-6.78%
2018-4.37%
2017-3.52%
201621.06%